Evidence map›Paper›PMID 32907583›Full record

ArticleJournal of nanobiotechnology2020

Plasma proteins facilitates placental transfer of polystyrene particles.

Michael M Gruber, Birgit Hirschmugl, Natascha Berger, Magdalena Holter, Snježana Radulović, Gerd Leitinger, Laura Liesinger, Andrea Berghold, Eva Roblegg, Ruth Birner-Gruenberger and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Tracking of [Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
  5. Review
  6. Therapeutic nanoparticle safety in pregnancy: Bridging knowledge gaps with environmental insights and a translational roadmap.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Nanoparticles at the maternal-fetal interface.Molecular and cellular endocrinology · 2023
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Michael M GruberDepartment of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, 8036, Graz, Austria.ORCID http://orcid.org/0000-0002-6871-6326
Birgit HirschmuglDepartment of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, 8036, Graz, Austria.ORCID http://orcid.org/0000-0002-2512-4750
Natascha BergerDepartment of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, 8036, Graz, Austria.ORCID http://orcid.org/0000-0002-2865-1142
Magdalena HolterInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Auenbruggerplatz 2, 8036, Graz, Austria.ORCID http://orcid.org/0000-0002-8355-3617
Snježana RadulovićDivision of Molecular Biology and Biochemistry, Gottfried Schatz Research Center, Medical University of Graz, Neue Stiftingtalstraße 6/VI, 8010, Graz, Austria.ORCID http://orcid.org/0000-0002-6791-8620
Gerd LeitingerResearch Unit Electron Microscopic Techniques, Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Neue Stiftingtalstraße 6/II, 8010, Graz, Austria.ORCID http://orcid.org/0000-0002-5281-9830
Laura LiesingerDiagnostic and Research Institute of Pathology, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Stiftingtalstrasse 6, 8010, Graz, Austria.
Andrea BergholdInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Auenbruggerplatz 2, 8036, Graz, Austria.
Eva RobleggInstitute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, University of Graz, Universitätsplatz 1/EG, 8010, Graz, Austria.ORCID http://orcid.org/0000-0002-5553-5147
Ruth Birner-GruenbergerDiagnostic and Research Institute of Pathology, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Stiftingtalstrasse 6, 8010, Graz, Austria.ORCID http://orcid.org/0000-0003-3950-0312
Vesna Bjelic-RadisicDepartment of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, 8036, Graz, Austria.
Christian WadsackDepartment of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, 8036, Graz, Austria. christian.wadsack@medunigraz.at.ORCID http://orcid.org/0000-0002-5589-8642
Medical University of Graz · ATTU Wien · ATUniversity of Graz · AT

Funding

Austrian Science Fund FWF DOC 31Austrian Science Fund FWF KLI 425
6 · The paper itself

Abstract

backgroundNanoparticles, which are exposed to biological fluids are rapidly interacting with proteins and other biomolecules forming a corona. In addition to dimension, charge and material the distinct protein corona influences the interplay of nanoparticles with tissue barriers. In this study we were focused on the impact of in situ formed human plasma protein corona on the transfer of 80 nm polystyrene nanoparticles (PS-particles) across the human placenta. To study materno-to fetal PS transfer we used the human ex vivo placental perfusion approach, which represents an intact and physiological tissue barrier. To analyze the protein corona of PS particles we performed shotgun proteomics of isolated nanoparticles before and after tissue exposure.

resultsHuman plasma incubated with PS-particles of 80 nm and subsequent formed protein corona enhanced the transfer across the human placenta compared to PS-corona formed by bovine serum albumin and dextran which served as a control. Quantitative and qualitative changes of plasma proteins determined the changes in PS transfer across the barrier. Based on the analysis of the PS-proteome two candidate proteins, namely human albumin and immunoglobulin G were tested if these proteins may account for the enhanced PS-transfer across the placenta. Interestingly, the protein corona formed by human albumin significantly induced the transfer of PS-particles across the tissue compared to the formed IgG-corona.

conclusionIn total we demonstrate the PS corona dynamically and significantly evolves upon crossing the human placenta. Thus, the initial composition of PS particles in the maternal circulation is not predictive for their transfer characteristics and performance once beyond the barrier of the placenta. The precise mechanism of these effects remains to be elucidated but highlights the importance of using well designed biological models when testing nanoparticles for biomedical applications.

Indexed as

Blood ProteinsFemaleHumansImmunoglobulin GImmunoglobulinsNanoparticlesParticle SizePerfusionPlacentaPolystyrenesPregnancyProtein CoronaSerum Albumin, BovineSerum Albumin, HumanSerum GlobulinsBlood ProteinsImmunoglobulin GImmunoglobulinsplasma protein fractionPolystyrenesProtein CoronaSerum Albumin, BovineSerum Albumin, HumanSerum GlobulinsBiocoronaDual ex vivo placental perfusionHuman placentaNanoparticlePlasma proteinsPolystyreneTransfer

Identifiers

PMID32907583
PMCPMC7487953
OpenAlexW3085408525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.